TW517063B - Biotin derivatives - Google Patents

Biotin derivatives Download PDF

Info

Publication number
TW517063B
TW517063B TW085108686A TW85108686A TW517063B TW 517063 B TW517063 B TW 517063B TW 085108686 A TW085108686 A TW 085108686A TW 85108686 A TW85108686 A TW 85108686A TW 517063 B TW517063 B TW 517063B
Authority
TW
Taiwan
Prior art keywords
gly
fmoc
asp
lys
arg
Prior art date
Application number
TW085108686A
Other languages
English (en)
Chinese (zh)
Inventor
Alfred Dr Jonczyk
Simon Dr Goodman
Beate Dr Diefenbach
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of TW517063B publication Critical patent/TW517063B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
TW085108686A 1995-09-14 1996-07-17 Biotin derivatives TW517063B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19534016A DE19534016A1 (de) 1995-09-14 1995-09-14 Biotinderivate

Publications (1)

Publication Number Publication Date
TW517063B true TW517063B (en) 2003-01-11

Family

ID=7772112

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085108686A TW517063B (en) 1995-09-14 1996-07-17 Biotin derivatives

Country Status (23)

Country Link
EP (1) EP0771818B1 (ja)
JP (1) JP4127325B2 (ja)
KR (1) KR970015597A (ja)
CN (1) CN1168738C (ja)
AT (1) ATE215558T1 (ja)
AU (1) AU719307B2 (ja)
BR (1) BR9603741A (ja)
CA (1) CA2185394C (ja)
CZ (1) CZ291506B6 (ja)
DE (2) DE19534016A1 (ja)
DK (1) DK0771818T3 (ja)
ES (1) ES2174007T3 (ja)
HU (1) HUP9602223A3 (ja)
MX (1) MX9604019A (ja)
NO (1) NO314694B1 (ja)
PL (1) PL316069A1 (ja)
PT (1) PT771818E (ja)
RU (1) RU2171807C2 (ja)
SI (1) SI0771818T1 (ja)
SK (1) SK283129B6 (ja)
TW (1) TW517063B (ja)
UA (1) UA41981C2 (ja)
ZA (1) ZA967765B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113827591A (zh) * 2021-11-09 2021-12-24 上海市肺科医院 生物素在制备治疗脓毒症药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US20010053766A1 (en) * 2000-02-11 2001-12-20 Janardan Kumar Method of treating disorders of the eye
KR100778633B1 (ko) * 2007-04-13 2007-11-28 성균관대학교산학협력단 비오틴과 비오틴-폴리에틸렌글리콜이 접합된 ｇｌｐ-1유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
US20110027209A1 (en) * 2008-04-08 2011-02-03 Merck Patent Gesellschaft Compositions Containing Cyclic Peptides And Methods Of Use
CN108956790A (zh) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315076B2 (ja) * 1973-09-27 1978-05-22
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5087561A (en) * 1990-06-28 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists modified at position 13 by biotin
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
DE4336758A1 (de) * 1993-10-28 1995-05-04 Merck Patent Gmbh Lineare Adhäsionsinhibitoren

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113827591A (zh) * 2021-11-09 2021-12-24 上海市肺科医院 生物素在制备治疗脓毒症药物中的应用

Also Published As

Publication number Publication date
CZ262996A3 (cs) 1998-02-18
UA41981C2 (uk) 2001-10-15
AU6551896A (en) 1997-03-20
EP0771818A3 (de) 1997-07-02
EP0771818A2 (de) 1997-05-07
HU9602223D0 (en) 1996-10-28
DE59608995D1 (de) 2002-05-08
SK283129B6 (sk) 2003-02-04
SK115696A3 (en) 1997-05-07
ATE215558T1 (de) 2002-04-15
NO963851L (no) 1997-03-17
RU2171807C2 (ru) 2001-08-10
PL316069A1 (en) 1997-03-17
CN1168738C (zh) 2004-09-29
BR9603741A (pt) 1998-06-02
JPH09124692A (ja) 1997-05-13
CA2185394C (en) 2007-05-01
JP4127325B2 (ja) 2008-07-30
ES2174007T3 (es) 2002-11-01
DE19534016A1 (de) 1997-03-20
ZA967765B (en) 1997-03-26
KR970015597A (ko) 1997-04-28
DK0771818T3 (da) 2002-07-29
NO314694B1 (no) 2003-05-05
AU719307B2 (en) 2000-05-04
CZ291506B6 (cs) 2003-03-12
EP0771818B1 (de) 2002-04-03
NO963851D0 (no) 1996-09-13
HUP9602223A3 (en) 1998-03-02
SI0771818T1 (en) 2002-10-31
CN1153784A (zh) 1997-07-09
PT771818E (pt) 2002-09-30
MX9604019A (es) 1997-03-29
CA2185394A1 (en) 1997-03-15
HUP9602223A2 (en) 1997-06-30

Similar Documents

Publication Publication Date Title
Garanger et al. Multivalent RGD synthetic peptides as potent α V β 3 integrin ligands
JP5358564B2 (ja) 環状ペプチドｃｘｃｒ４アンタゴニスト
ES2404052T3 (es) Péptidos que tienen actividad farmacológica para el tratamiento de trastornos asociados con la migración celular alterada, tal como el cáncer
TWI247748B (en) Peptide antiangiogenic drugs
JP4786047B2 (ja) ペプチド誘導体
McElroy et al. Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor
JPH10506608A (ja) 白血球接着のインヒビター
CN103096915A (zh) 免疫抑制调节化合物
JPH09509142A (ja) 新規のインテグリン結合ペプチド
BRPI0717441B1 (pt) Composto, medicamento, e, uso do derivado de metastina
JP2008540340A (ja) カドヘリン介在過程を調節する化合物及び方法
US12115224B2 (en) Polypeptide conjugates for intracellular delivery of stapled peptides
KR100286242B1 (ko) 돌라스타틴 유도체
JP2000512277A (ja) ペプチド誘導体
TWI226890B (en) Cyclic peptide derivatives as inhibitors of integrin alphavbeta6
CZ20013318A3 (cs) Noví LH-RH-antagonisté se zlepąenými vlastnostmi rozpustnosti
CA2343924A1 (en) Peptide derivative
AU641366B2 (en) Peptide compounds
TW517063B (en) Biotin derivatives
AU2004253475A1 (en) Leukocyte internalized peptide-drug conjugates
JP2001514659A (ja) ドラスタチン−１５誘導体とタキサンとの併用
CN102325540A (zh) 具有至少一个合成的氨基酸替换的神经肽y的类似物
MXPA01013247A (es) Inhibidores de la integrina alfa-v-beta-6.
WO1999065944A1 (en) PEPTIDE INHIBITORS OF αVβ3 AND αVβ¿5?
KR20010101178A (ko) αｖβ６ 인테그린 저해제

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees